You are here

Fragile X Syndrome Market Spotlight, 2019 - There Have Been 5 Licensing & Asset Acquisition Deals Involving FXS Drugs During 2014-2019

DUBLIN, June 27, 2019 /PRNewswire/ -- The "Market Spotlight: Fragile X Syndrome" report has been added to ResearchAndMarkets.com's offering.

This Market Spotlight report covers the Fragile X Syndrome market, comprising key pipeline drugs, clinical trials, upcoming events, patent information, recent events and analyst opinion, a discussion on disease epidemiology, and licensing and asset acquisition deals.

Key Takeaways

  • Based on cohorts of children with special educational needs, prevalence of fragile X syndrome (FXS) is estimated to be 1 in 4,000 in males, and 1 in 8,000 in females.
  • The majority of the industry-sponsored drugs in active clinical development for FXS are in Phase II, with only one drug in Phase III.
  • Therapies in mid- and late-stage development focus on targets such as cannabinoid-1/cannabinoid-2 receptor, phosphodiesterase 4, insulin-like growth factor-1 receptor, and GABA-A receptor. The majority of the pipeline drugs are administered via the oral and intravenous routes, while one drug is available in a topical formulation.
  • High-impact upcoming events in the FXS space comprise topline Phase III trial results for ZYN-002, and topline Phase II trial results for OV101.
  • The overall likelihood of approval of a Phase I neurodevelopmental disorders asset is 4.8%, and the average probability a drug advances from Phase III is 28.6%. Drugs, on average, take 8.3 years from Phase I to approval, compared to 9.6 years in the overall neurology space.
  • There have been five licensing and asset acquisition deals involving FXS drugs during 2014-19. The exclusive licensing agreement in 2017 between Boehringer Ingelheim and Autifony Therapeutics, worth $737.5m, for a collaboration on a novel therapeutic approach to a range of CNS disorders, was the largest deal during the period.
  • All clinical trials for FXS have been in Phase II, with no Phase III trials to date.
  • The US leads in terms of the number of FXS clinical trials globally.

Key Topics Covered

OVERVIEW

KEY TAKEAWAYS

DISEASE BACKGROUND

TREATMENT

EPIDEMIOLOGY

PIPELINE DRUGS

RECENT EVENTS AND ANALYST OPINION

  • ZYN-002 for FXS (September 28, 2017)

KEY UPCOMING EVENTS

PROBABILITY OF SUCCESS

LICENSING AND ASSET ACQUISITION DEALS

  • Shionogi Picks Up Asia Rights To Tetra's Cognitive Candidate

PARENT PATENTS

CLINICAL TRIAL LANDSCAPE

  • Sponsors by status
  • Sponsors by phase

BIBLIOGRAPHY

APPENDIX

LIST OF FIGURES
Figure 1: Overview of pipeline drugs for FXS in the US
Figure 2: Pipeline drugs for FXS, by company
Figure 3: Pipeline drugs for FXS, by drug type
Figure 4: Pipeline drugs for FXS, by classifications
Figure 5: ZYN-002 for FXS (September 28, 2017): Phase II - FAB-C
Figure 6: Key upcoming events in FXS
Figure 7: Probability of success in the FXS pipeline
Figure 8: Licensing and asset acquisition deals in FXS, 2014-19
Figure 9: Parent patents in FXS
Figure 10: Clinical trials in FXS
Figure 11: Top 10 drugs for clinical trials in FXS
Figure 12: Top 10 companies for clinical trials in FXS
Figure 13: Trial locations in FXS
Figure 14: FXS trials status
Figure 15: FXS trials sponsors, by phase

LIST OF TABLES
Table 1: Pipeline drugs for FXS in the US
Table 2: ZYN-002 for FXS (September 28, 2017)

For more information about this report visit https://www.researchandmarkets.com/r/y6rdm7

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

Media Contact:

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

Cision View original content:http://www.prnewswire.com/news-releases/fragile-x-syndrome-market-spotlight-2019---there-have-been-5-licensing--asset-acquisition-deals-involving-fxs-drugs-during-2014-2019-300875453.html

SOURCE Research and Markets